Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Because of the strong relationships the Organon sales team has with these healthcare providers, we expect them to be well positioned to detail XACIATO |
| Obviously very excited that the study is starting |
| I'm excited to share today the recent strides we've made to advance innovative therapies for women with our most promising near-term opportunities |
| But I think it's really wonderful to be in a position where we're able to say and not in a boasty way, but just state reality |
| In summary, I am very excited about the progress we've made on our late-stage program since our last call in August |
| Second, we shared additional positive data from our Phase 2b RESPONSE study of Sildenafil Cream, which has the potential to be the first FDA-approved treatment for any form of sexual arousal disorder in women |
| We believe we have an exceptionally strong pipeline of product candidates that positions us well for the short, medium and long-term |
| And ultimately, we believe we are uniquely positioned to improve quality of life for millions of women of women |
| So we have - so what's nice about that I should stress is it puts Daré in a nice position and being able to think about what makes sense for Daré and our shareholders |
| So as we noted upfront, we're very proud that we are in collaboration with some of the leaders in women's health, including Organon and Bayer |
| These activities will help set the foundation to maximize the value of this disruptive technology |
| We believe this is a promising untapped market given the numerous equivalent products approved for men, not only Viagra, but also Cialis and Levitra, to name a few |
| In addition to providing innovation as a non-hormonal contraceptive, the clear differentiation and disruptive potential of Ovaprene is in its convenience and potential efficacy |
| Sildenafil, which is a PDE5 inhibitor, is the active ingredient in a tablet for oral administration currently marketed under the brand name Viagra for the treatment of ED erectile dysfunction in men, which was undoubtedly one of the most successful prescription products ever launched |
| Since the beginning of the third quarter, we have had several important achievements |
| So I appreciate you dialing in to hear about our recent updates, and our ongoing commitment to drive value for all of Daré's stakeholders by addressing unmet needs in women's health |
| Last week, we announced additional positive data from our Phase 2b RESPONSE study of Sildenafil Cream, having completed our study analysis in preparation for our upcoming FDA meeting |
| And third, we made further progress toward patient enrollment for the anticipated start of our pivotal Phase 3 study of Ovaprene, our potentially first-in-class hormone-free monthly intravaginal contraceptive candidates |
| Sildenafil Cream is a very interesting program |
| Additionally, we are actively engaging our commercialization collaborators, including leading players in women's health, Organon and Bayer as we steadily execute on our mission to accelerate innovative treatments that women want and need |
| In the current challenging market, we have reduced costs and are exploring additional opportunities to reduce costs when appropriate and where appropriate, but seeking to do so without compromising our focus on investing and cultivating our leading product candidates |
| As we have communicated on previous calls, Organon's go-to-market strategy leverages the knowledge and experience of the established NEXPLANON commercial team |
| We believe Ovaprene has the potential to be a disruptive product in the contraceptive category and potentially life-changing for women who cannot take hormone-based therapies such as some cancer patients or those who would prefer not to do so |
| Thank you for the great questions, and thanks for asking about Ovaprene |
| And as you'll hear from Lisa later on this call, we do all of this with thoughtful and efficient capital deployment and leveraging non-dilutive sources of capital wherever feasible |
| Great |
| Overall, we continue to advance our key pipeline programs, each of which, if approved, represents a potential first line or first-in-category opportunity |
| It goes without saying that we at Daré are thrilled that XACIATO is now available in the U.S., and I look forward to reporting on XACIATO's progress in the months ahead for all Daré stakeholders |
| For those of you who are newer to the story, Daré's business strategy is to assemble in advance a portfolio of differentiated product candidates that address meaningful unmet needs that we've identified in women's health, and then to monetize the value of our portfolio's clinical and regulatory advances over the near and long-term |
| And I say all of that to say really in the field of women's health and women's sexual health, quite frankly, Daré has seen is very much the thought leader in this area |
| Statement |
|---|
| They're frustrated with their sexual problems |
| Our comprehensive loss for the third quarter was approximately $8.3 million |
| They experienced guilt about their sexual difficulties and they are likely to feel sexually inadequate, inferior and embarrassed |
| Women who experienced no or low sexual arousal are bothered by and dissatisfied with their sex lives |
| Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties |
Please consider a small donation if you think this website provides you with relevant information